Literature DB >> 2701924

Hepatobiliary pathology in patients with cystic fibrosis.

M Sinaasappel1.   

Abstract

Overt liver disease in cystic fibrosis is a rare condition. Only 1-5% of all patients show a severe disturbance of the liver cell function or portal hypertension. In contrast, liver architecture is much more often disturbed at post mortem examination. The experience is that liver pathology increases with age which will result in rising numbers of patients in the future parallel to the increasing life expectancy of the patients. Bile plugs are commonly found in the portal tract and probably represent the essential abnormality of the liver in CF. Recently new methods have been developed for the investigation of the bile synthesis which will be helpful in the understanding of the CF defect in the liver.

Entities:  

Mesh:

Year:  1989        PMID: 2701924     DOI: 10.1111/apa.1989.78.s363.45

Source DB:  PubMed          Journal:  Acta Paediatr Scand Suppl        ISSN: 0300-8843


  5 in total

Review 1.  Cystic fibrosis, pathophysiological and clinical aspects.

Authors:  H J Neijens; M Sinaasappel; R de Groot; J C de Jongste; S E Overbeek
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

2.  Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease.

Authors:  H A Wyatt; A Dhawan; P Cheeseman; G Mieli-Vergani; J F Price
Journal:  Arch Dis Child       Date:  2002-03       Impact factor: 3.791

3.  Partial splenectomy in cystic fibrosis patients with hypersplenism.

Authors:  G H Thalhammer; E Eber; S Uranüs; J Pfeifer; M S Zach
Journal:  Arch Dis Child       Date:  2003-02       Impact factor: 3.791

4.  Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up.

Authors:  J Feigelson; C Anagnostopoulos; M Poquet; Y Pecau; A Munck; J Navarro
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

5.  Cholic acid induces a Cftr dependent biliary secretion and liver growth response in mice.

Authors:  Frank A J A Bodewes; Marcel J Bijvelds; Willemien de Vries; Juul F W Baller; Annette S H Gouw; Hugo R de Jonge; Henkjan J Verkade
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.